V. V. Smol'Nikova
V. V. Smol'Nikova has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- A. E. Shcherba
State Institution “Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology
6 shared publications - O. O. Rummo
Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology
6 shared publications - S. I. Krivenko
Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology
6 shared publications - S. V. Korotkov
Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology
5 shared publications - E. A. Nazarova
Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology
4 shared publications - V. Yu. Grinevich
Minsk Scientific and Practical Center of Surgery, Transplantation and Hematology
4 shared publications
Latest Publications
- Open Access
- 17 September 2025
- Published by IPO Association of Transplantologists in Transplantologiya. The Russian Journal of Transplantation
- Vol. 17 (3) , 232-245
Mesenchymal stem cells in liver transplantation: аssessment of long-term results
Introduction. Transplantation is an effective method of treating patients with end stage liver diseases. Long-term results are determined by two main factors: the development of immunological complications and calcineurin inhibitor nephrotoxity. Application of mesenchymal stem cells (MSCs), which modulate the immune response, is a promising effective method to optimize the treatment results in patients after liver transplantation.The objective of the study was to evaluate the long-term results of mesenchymal stem cells application in liver transplantation.Material and methods. A retrospective study was performed, which included 186 patients after liver transplantation (2015–2023). The MSC group (n=93) received MSCs according to four protocols: local, systemic, combined administration, therapy for acute kidney injury; the control group (n=93) received the standard treatment. The median follow-up was 3 (2;5) years, the follow-up period being from 1-8 years. The patient survival, graft and renal function, depth of immunosuppressive therapy, anti-HLA antibody levels, and lymphocyte immunophenotype were assessed.Results. In the MSC group the incidence of immunological dysfunction of the liver allograft was decreased (22% versus 40%, pConclusion. Using MSCs in liver transplantation improves long-term outcomes by reducing the incidence of immunological complications, preserves the renal function, and reduces the need for high-dose immunosuppression.
- 17 September 2025
- Published by IPO Association of Transplantologists in Transplantologiya. The Russian Journal of Transplantation
- Vol. 17 (3) , 232-245
Open AccessMesenchymal stem cells in liver transplantation: аssessment of long-term results
Introduction. Transplantation is an effective method of treating patients with end stage liver diseases. Long-term results are determined by two main factors: the development of immunological complications and calcineurin inhibitor nephrotoxity. Application of mesenchymal stem cells (MSCs), which modulate the immune response, is a promising effective method to optimize the treatment results in patients after liver transplantation.The objective of the study was to evaluate the long-term results of mesenchymal stem cells application in liver transplantation.Material and methods. A retrospective study was performed, which included 186 patients after liver transplantation (2015–2023). The MSC group (n=93) received MSCs according to four protocols: local, systemic, combined administration, therapy for acute kidney injury; the control group (n=93) received the standard treatment. The median follow-up was 3 (2;5) years, the follow-up period being from 1-8 years. The patient survival, graft and renal function, depth of immunosuppressive therapy, anti-HLA antibody levels, and lymphocyte immunophenotype were assessed.Results. In the MSC group the incidence of immunological dysfunction of the liver allograft was decreased (22% versus 40%, pConclusion. Using MSCs in liver transplantation improves long-term outcomes by reducing the incidence of immunological complications, preserves the renal function, and reduces the need for high-dose immunosuppression.
- Open Access
- 31 August 2025
- Published by Publishing House Belorusskaya Nauka in Proceedings of the National Academy of Sciences of Belarus, Medical series
- Vol. 22 (3) , 220-231
Characteristics of immune status in patients after liver transplantation with mesenchymal stem cell therapy
The aim of the study was evaluation of the characteristics of the immunophenotype of peripheral blood mononuclear cells in patients after liver transplantation with systemic mesenchymal stem cells (MSCs) therapy. A randomized prospective study was conducted involving 30 recipients. Patients in the MSC group (n = 15) received standard immunosuppressive therapy in combination with systemic application of MSCs, and patients in the control group (n = 15) received only standard immunosuppression. The analysis of the immunophenotype of peripheral blood mononuclear cells was performed by flow cytometry with assessment of the main populations and subpopulations of lymphocytes and dendritic cells. The application of MSCs resulted in an immunotolerant phenotype, characterized by an increase in the level of regulatory T cells and B1a lymphocytes, a decrease in the number of effector CD4+ memory T cells and B lymphocytes, as well as a modulation of dendritic cells activity. The MSC group demonstrated a lower incidence of acute rejection (20 % compared to 33 %), lower expression of MMP10 in the graft, accelerated recovery of liver function, and the ability to reduce the dose of Tacrolimus without the risk of rejection. These results indicate the potential of MSCs to serve as an additional method of immunosuppression in liver transplantation
- 31 August 2025
- Published by Publishing House Belorusskaya Nauka in Proceedings of the National Academy of Sciences of Belarus, Medical series
- Vol. 22 (3) , 220-231
Open AccessCharacteristics of immune status in patients after liver transplantation with mesenchymal stem cell therapy
The aim of the study was evaluation of the characteristics of the immunophenotype of peripheral blood mononuclear cells in patients after liver transplantation with systemic mesenchymal stem cells (MSCs) therapy. A randomized prospective study was conducted involving 30 recipients. Patients in the MSC group (n = 15) received standard immunosuppressive therapy in combination with systemic application of MSCs, and patients in the control group (n = 15) received only standard immunosuppression. The analysis of the immunophenotype of peripheral blood mononuclear cells was performed by flow cytometry with assessment of the main populations and subpopulations of lymphocytes and dendritic cells. The application of MSCs resulted in an immunotolerant phenotype, characterized by an increase in the level of regulatory T cells and B1a lymphocytes, a decrease in the number of effector CD4+ memory T cells and B lymphocytes, as well as a modulation of dendritic cells activity. The MSC group demonstrated a lower incidence of acute rejection (20 % compared to 33 %), lower expression of MMP10 in the graft, accelerated recovery of liver function, and the ability to reduce the dose of Tacrolimus without the risk of rejection. These results indicate the potential of MSCs to serve as an additional method of immunosuppression in liver transplantation
- Open Access
- 28 August 2025
- Published by Publishing House Belorusskaya Nauka in Doklady of the National Academy of Sciences of Belarus
- Vol. 69 (4) , 314–321
Comparative analysis of the profile of expression of molecular markers of mesenchymal stem cells obtained from placental-umbilical cord complex tissues, adipose tissue and bone marrow
Mesenchymal stem cells (MSCs) are multifunctional adult stem cells that can be derived from various tissues, such as adult adipose tissue, peripheral blood, bone marrow, neonatal placenta, and umbilical cord tissue. MSCs have the capacity for self-renewal and multidirectional differentiation. Despite the absence of differences in the expression of the main surface markers, MSCs obtained from tissues of the placenta-umbilical cord complex, adipose tissue and bone marrow differ significantly in their molecular profile. Cellular heterogeneity is ubiquitous across MSC cultures from different species and tissues. During the course of the study, the expression level of cell surface markers that characterize the heterogeneity of MSCs obtained from various sources was assessed. MSCs from all tissues express typical MSC markers on their surface, including CD13, CD73, CD105 and CD90, in the absence of expression of hematopoietic markers (CD14, CD34 and CD45), costimulatory molecules CD86, membrane protein CD154, adhesion molecules CD15, and markers of embryonic stem cells (TRA-1-81 and TRA-1-60R). However, they differed in the expression of stemness markers (October 4, Nanog), coinhibitory molecules (CD273, CD274, and CD200), cell adhesion molecules CD146, surface antigen SSEA-4, and transcription factor GATA4. The results on the molecular profile of MSCs as a heterogeneous cell population allow for the scientific substantiation of the choice of tissue source for the creation of biomedical cell products with specified therapeutic properties.
- 28 August 2025
- Published by Publishing House Belorusskaya Nauka in Doklady of the National Academy of Sciences of Belarus
- Vol. 69 (4) , 314–321
Open AccessComparative analysis of the profile of expression of molecular markers of mesenchymal stem cells obtained from placental-umbilical cord complex tissues, adipose tissue and bone marrow
Mesenchymal stem cells (MSCs) are multifunctional adult stem cells that can be derived from various tissues, such as adult adipose tissue, peripheral blood, bone marrow, neonatal placenta, and umbilical cord tissue. MSCs have the capacity for self-renewal and multidirectional differentiation. Despite the absence of differences in the expression of the main surface markers, MSCs obtained from tissues of the placenta-umbilical cord complex, adipose tissue and bone marrow differ significantly in their molecular profile. Cellular heterogeneity is ubiquitous across MSC cultures from different species and tissues. During the course of the study, the expression level of cell surface markers that characterize the heterogeneity of MSCs obtained from various sources was assessed. MSCs from all tissues express typical MSC markers on their surface, including CD13, CD73, CD105 and CD90, in the absence of expression of hematopoietic markers (CD14, CD34 and CD45), costimulatory molecules CD86, membrane protein CD154, adhesion molecules CD15, and markers of embryonic stem cells (TRA-1-81 and TRA-1-60R). However, they differed in the expression of stemness markers (October 4, Nanog), coinhibitory molecules (CD273, CD274, and CD200), cell adhesion molecules CD146, surface antigen SSEA-4, and transcription factor GATA4. The results on the molecular profile of MSCs as a heterogeneous cell population allow for the scientific substantiation of the choice of tissue source for the creation of biomedical cell products with specified therapeutic properties.
- Open Access
- 8 January 2025
- Published by Publishing House Belorusskaya Nauka in Doklady of the National Academy of Sciences of Belarus
- Vol. 68 (6) , 483-492
Usage of mesenchymal cells from the human placental-umbilical complex in the correction of liver failure in patients with decompensated liver cirrhosis
Acute-on-chronic liver failure is an acute liver decompensation in cirrhotic patients, which leads to organ failures and high short-term mortality. The treatment is based on the management of complications and, in severe cases, liver transplantation. Liver transplantation is the most effective treatment, but the lack of donor livers and a high cost of transplantation limit its broad application. Human placenta-umbilical cord complex derived mesenchymal stem cells (MSCs) can be considered as an allogeneic source for liver disease. The aim of the study was to assess the safety and potential effectiveness of systemic administration of mesenchymal cells from the human placental-umbilical cord complex for liver failure correction in patients with decompensated cirrhosis of the liver. An open interventional prospective case-control study was conducted, including 40 patients over 18 years of age with decompensated liver cirrhosis who were hospitalized awaiting liver transplantation. Laboratory efficacy of therapy was confirmed by a significant decrease in a total bilirubin level by 39 %, an increase in total protein was noted (by 11 %), as well as stabilization of coagulopathy (decrease in INR by 25 %). Systemic administration of mesenchymal cells of placental origin is a promising therapeutic option for patients with decompensated liver cirrhosis, allowing one to increase the waiting period for emergency liver transplantation and stabilize the clinical course of the disease.
- 8 January 2025
- Published by Publishing House Belorusskaya Nauka in Doklady of the National Academy of Sciences of Belarus
- Vol. 68 (6) , 483-492
Open AccessUsage of mesenchymal cells from the human placental-umbilical complex in the correction of liver failure in patients with decompensated liver cirrhosis
Acute-on-chronic liver failure is an acute liver decompensation in cirrhotic patients, which leads to organ failures and high short-term mortality. The treatment is based on the management of complications and, in severe cases, liver transplantation. Liver transplantation is the most effective treatment, but the lack of donor livers and a high cost of transplantation limit its broad application. Human placenta-umbilical cord complex derived mesenchymal stem cells (MSCs) can be considered as an allogeneic source for liver disease. The aim of the study was to assess the safety and potential effectiveness of systemic administration of mesenchymal cells from the human placental-umbilical cord complex for liver failure correction in patients with decompensated cirrhosis of the liver. An open interventional prospective case-control study was conducted, including 40 patients over 18 years of age with decompensated liver cirrhosis who were hospitalized awaiting liver transplantation. Laboratory efficacy of therapy was confirmed by a significant decrease in a total bilirubin level by 39 %, an increase in total protein was noted (by 11 %), as well as stabilization of coagulopathy (decrease in INR by 25 %). Systemic administration of mesenchymal cells of placental origin is a promising therapeutic option for patients with decompensated liver cirrhosis, allowing one to increase the waiting period for emergency liver transplantation and stabilize the clinical course of the disease.
- Open Access
- 31 January 2023
- Published by Practical Medicine Publishing House in Annals of Critical Care
- No. 1,p. 71-82
The use of mesenchymal stem cells in the treatment of severe forms of new coronavirus infection COVID-19: a prospective observational study
INTRODUCTION: One of the promising treatments for COVID-19 aimed at correcting the immune response and reducing the level of pro-inflammatory cytokines is the use of mesenchymal stem cells (MSCs). There is evidence that MSCs, due to various mechanisms, are able to suppress the cytokine storm in patients with COVID-19. Thus, the use of MSCs can contribute to the suppression of inflammation and the regulation of immune homeostasis in patients with severe COVID-19. OBJECTIVE: Evaluation of the effect of mesenchymal stem cell (MSC) therapy on the course of severe forms of novel coronavirus infection, accompanied by “cytokine storm”. MATERIALS AND METHODS: A prospective single-center study included 39 patients treated for coronavirus infection on the basis of the intensive care unit and, after randomization, randomly divided into control (n = 16) and study groups (n = 23). An assessment of clinical, laboratory parameters in both groups and a cytokine profile in the study group was carried out. Outcomes were compared, the incidence of complications and clinical and laboratory parameters in both groups, and the cytokine profile in the study group. RESULTS: The use of MSCs in patients with severe forms of COVID-19 affected the outcomes of the disease, the duration of stay on mechanical ventilation, the course of acute respiratory distress syndrome (ARDS) (an increase in the oxygenation index in patients of the study group by 5, 7 days from administration in comparison with the control group). CONCLUSIONS: In patients treated with MSCs, there was a significant decrease in a number of pro-inflammatory cytokines.
- 31 January 2023
- Published by Practical Medicine Publishing House in Annals of Critical Care
- No. 1,p. 71-82
Open AccessThe use of mesenchymal stem cells in the treatment of severe forms of new coronavirus infection COVID-19: a prospective observational study
INTRODUCTION: One of the promising treatments for COVID-19 aimed at correcting the immune response and reducing the level of pro-inflammatory cytokines is the use of mesenchymal stem cells (MSCs). There is evidence that MSCs, due to various mechanisms, are able to suppress the cytokine storm in patients with COVID-19. Thus, the use of MSCs can contribute to the suppression of inflammation and the regulation of immune homeostasis in patients with severe COVID-19. OBJECTIVE: Evaluation of the effect of mesenchymal stem cell (MSC) therapy on the course of severe forms of novel coronavirus infection, accompanied by “cytokine storm”. MATERIALS AND METHODS: A prospective single-center study included 39 patients treated for coronavirus infection on the basis of the intensive care unit and, after randomization, randomly divided into control (n = 16) and study groups (n = 23). An assessment of clinical, laboratory parameters in both groups and a cytokine profile in the study group was carried out. Outcomes were compared, the incidence of complications and clinical and laboratory parameters in both groups, and the cytokine profile in the study group. RESULTS: The use of MSCs in patients with severe forms of COVID-19 affected the outcomes of the disease, the duration of stay on mechanical ventilation, the course of acute respiratory distress syndrome (ARDS) (an increase in the oxygenation index in patients of the study group by 5, 7 days from administration in comparison with the control group). CONCLUSIONS: In patients treated with MSCs, there was a significant decrease in a number of pro-inflammatory cytokines.
- Open Access
- 1 January 2020
- Published by Grodno State Medical University in Hepatology and Gastroenterology
- Vol. 4 (2) , 177-183
THE OPPORTUNITIES OF NON-INVASIVE LIVER GRAFT REJECTION DIAGNOSTICS BY USING TERMINALLY DIFFERENTIATED EFFECTOR CD8+ T-LYMPHOCYTES
Background. Immune-mediated graft dysfunction with the prevalence of 40% is one of the main problems of modern transplantology. Although percutaneous liver graft biopsy is associated with the development of different complications occurring in 2,2% of cases and can also lead to fatal outcome. Objective – to develop a noninvasive method of graft dysfunction diagnostics in the late post-transplant period using terminally differentiated effector CD8+ T-lymphocytes. Material and methods. There was carried out a single center observational retrospective case-control pilot study, including 45 recipients after orthotopic liver transplantation. According to the postoperative clinical course the patients were stratifed into 2 groups depending on the presence of graft rejection episodes. All patients got immunosuppressive therapy after liver transplantation. Immunophenotypes of the recipients were determined by flow cytometry method. Percutaneous liver graft biopsy was performed in all patients, the results of histological examination were evaluated according to the international Banff schema for grading liver allograft rejection. Results. The results of liver biopsies showed that 14 (31%) out of 45 patients had morphological signs of rejection. The patients with rejection had a reliably higher level of CD8+ Temra cells absolute number (0,23 (0,14;0,38) x 109/l) in comparison to those without rejection (0,09) (0,034;0,16) x 109/l (p=0,034)). The results of ROC-analysis have shown that the most optimal cut-off threshold of CD8+ T-lymphocytes level in immune-mediated graft dysfunction diagnostics in the late post-transplant period is 0,1882x109/l; sensitivity and specifcity in this case being 73,33 (95%; 44,9-92,0) and 96,55 (95%; 82,2-99,4) respectively. Conclusions. The increase of terminally differentiated effector CD8+ T-lymphocytes absolute number has diagnostic importance in patients with immune-mediated graft dysfunction in the late post-transplant period. High sensitivity and specifcity of cut-off threshold of CD8+ Temra lymphocytes absolute number in patients after liver transplantation as well as reliable difference between cell number in patients with normal postoperative period and in patients with immune-mediated graft dysfunction allow considering T-lymphocyte subpopulation as a rejection predictor in the late post-transplant period. The correlation between CD8+ T-lymphocyte absolute number and the results of histological examination makes the former an alternative and, what is more, safe noninvasive method in early diagnostics of liver graft rejection.
- 1 January 2020
- Published by Grodno State Medical University in Hepatology and Gastroenterology
- Vol. 4 (2) , 177-183
Open AccessTHE OPPORTUNITIES OF NON-INVASIVE LIVER GRAFT REJECTION DIAGNOSTICS BY USING TERMINALLY DIFFERENTIATED EFFECTOR CD8+ T-LYMPHOCYTES
Background. Immune-mediated graft dysfunction with the prevalence of 40% is one of the main problems of modern transplantology. Although percutaneous liver graft biopsy is associated with the development of different complications occurring in 2,2% of cases and can also lead to fatal outcome. Objective – to develop a noninvasive method of graft dysfunction diagnostics in the late post-transplant period using terminally differentiated effector CD8+ T-lymphocytes. Material and methods. There was carried out a single center observational retrospective case-control pilot study, including 45 recipients after orthotopic liver transplantation. According to the postoperative clinical course the patients were stratifed into 2 groups depending on the presence of graft rejection episodes. All patients got immunosuppressive therapy after liver transplantation. Immunophenotypes of the recipients were determined by flow cytometry method. Percutaneous liver graft biopsy was performed in all patients, the results of histological examination were evaluated according to the international Banff schema for grading liver allograft rejection. Results. The results of liver biopsies showed that 14 (31%) out of 45 patients had morphological signs of rejection. The patients with rejection had a reliably higher level of CD8+ Temra cells absolute number (0,23 (0,14;0,38) x 109/l) in comparison to those without rejection (0,09) (0,034;0,16) x 109/l (p=0,034)). The results of ROC-analysis have shown that the most optimal cut-off threshold of CD8+ T-lymphocytes level in immune-mediated graft dysfunction diagnostics in the late post-transplant period is 0,1882x109/l; sensitivity and specifcity in this case being 73,33 (95%; 44,9-92,0) and 96,55 (95%; 82,2-99,4) respectively. Conclusions. The increase of terminally differentiated effector CD8+ T-lymphocytes absolute number has diagnostic importance in patients with immune-mediated graft dysfunction in the late post-transplant period. High sensitivity and specifcity of cut-off threshold of CD8+ Temra lymphocytes absolute number in patients after liver transplantation as well as reliable difference between cell number in patients with normal postoperative period and in patients with immune-mediated graft dysfunction allow considering T-lymphocyte subpopulation as a rejection predictor in the late post-transplant period. The correlation between CD8+ T-lymphocyte absolute number and the results of histological examination makes the former an alternative and, what is more, safe noninvasive method in early diagnostics of liver graft rejection.
- Open Access
- 20 August 2019
- Published by Vitebsk State Medical University in Novosti Khirurgii
- Vol. 27 (4) , 409-420
Value of Assessment of Lymphocytes Subpopulations Numbers in Peripheral Blood for Diagnosis of Cellular Rejection after Kidney Transplantion
- 20 August 2019
- Published by Vitebsk State Medical University in Novosti Khirurgii
- Vol. 27 (4) , 409-420
Open AccessValue of Assessment of Lymphocytes Subpopulations Numbers in Peripheral Blood for Diagnosis of Cellular Rejection after Kidney Transplantion
- 1 June 2000
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 129 (6) , 567-570
Cytokine-induced differentiation and proliferation of human T lymphocytesin vitro: Effects of interleukin 2 and interleukin 6
The contents of CD8+, CD4+CD8+, CD3+HLA-DR+, CD+INF-γ+ T cells, and natural killers (CD16+56+) and NK/T cells (CD16+56+CD3+) increase after 7-day culturing in the presence of interleukin-2. The number of apoptotic cells and cells in S-, and G2+M phases of the cell cycle also increased. Interleukin-6 predominantly induced proliferation of CD3+HLA-DR+ T cells and G2+M mitotic cells.
- 1 June 2000
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 129 (6) , 567-570
Cytokine-induced differentiation and proliferation of human T lymphocytesin vitro: Effects of interleukin 2 and interleukin 6
The contents of CD8+, CD4+CD8+, CD3+HLA-DR+, CD+INF-γ+ T cells, and natural killers (CD16+56+) and NK/T cells (CD16+56+CD3+) increase after 7-day culturing in the presence of interleukin-2. The number of apoptotic cells and cells in S-, and G2+M phases of the cell cycle also increased. Interleukin-6 predominantly induced proliferation of CD3+HLA-DR+ T cells and G2+M mitotic cells.